475 related articles for article (PubMed ID: 19210352)
21. FIP1L1-PDGFRA positive chronic eosinophilic leukaemia and associated central nervous system involvement.
Williams C; Kalra S; Nath U; Bown N; Wilson V; Wilkins BS; Neylon AJ
J Clin Pathol; 2008 May; 61(5):677-80. PubMed ID: 18256119
[TBL] [Abstract][Full Text] [Related]
22. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy.
Pardanani A; Ketterling RP; Brockman SR; Flynn HC; Paternoster SF; Shearer BM; Reeder TL; Li CY; Cross NC; Cools J; Gilliland DG; Dewald GW; Tefferi A
Blood; 2003 Nov; 102(9):3093-6. PubMed ID: 12842979
[TBL] [Abstract][Full Text] [Related]
23. The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro.
von Bubnoff N; Gorantla SP; Engh RA; Oliveira TM; Thöne S; Aberg E; Peschel C; Duyster J
Oncogene; 2011 Feb; 30(8):933-43. PubMed ID: 20972453
[TBL] [Abstract][Full Text] [Related]
24. Successful imatinib treatment of cardiac involvement of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia followed by severe hepatotoxicity.
Arai A; Yan W; Wakabayashi S; Hayashi S; Inazawa J; Miura O
Int J Hematol; 2007 Oct; 86(3):233-7. PubMed ID: 17988989
[TBL] [Abstract][Full Text] [Related]
25. FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells.
Crescenzi B; Chase A; Starza RL; Beacci D; Rosti V; Gallì A; Specchia G; Martelli MF; Vandenberghe P; Cools J; Jones AV; Cross NC; Marynen P; Mecucci C
Leukemia; 2007 Mar; 21(3):397-402. PubMed ID: 17215855
[TBL] [Abstract][Full Text] [Related]
26. Long-term outcomes of imatinib in patients with FIP1L1/ PDGFRA associated chronic eosinophilic leukemia: experience of a single center in China.
Qu SQ; Qin TJ; Xu ZF; Zhang Y; Ai XF; Li B; Zhang HL; Fang LW; Pan LJ; Hu NB; Xiao ZJ
Oncotarget; 2016 May; 7(22):33229-36. PubMed ID: 27120808
[TBL] [Abstract][Full Text] [Related]
27. Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study.
Metzgeroth G; Walz C; Erben P; Popp H; Schmitt-Graeff A; Haferlach C; Fabarius A; Schnittger S; Grimwade D; Cross NC; Hehlmann R; Hochhaus A; Reiter A
Br J Haematol; 2008 Dec; 143(5):707-15. PubMed ID: 18950453
[TBL] [Abstract][Full Text] [Related]
28. Response to imatinib mesylate in patients with hypereosinophilic syndrome.
Arefi M; García JL; Briz MM; de Arriba F; Rodríguez JN; Martín-Núñez G; Martínez J; López J; Suárez JG; Moreno MJ; Merino MA; Gutiérrez NC; Hernández-Rivas JM
Int J Hematol; 2012 Sep; 96(3):320-6. PubMed ID: 22806436
[TBL] [Abstract][Full Text] [Related]
29. The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-alpha-expressing cells through caspase-3-mediated cleavage of Mcl-1.
Pan J; Quintás-Cardama A; Manshouri T; Giles FJ; Lamb P; Tefferi A; Cortes J; Kantarjian H; Verstovsek S
Leukemia; 2007 Jul; 21(7):1395-404. PubMed ID: 17495975
[TBL] [Abstract][Full Text] [Related]
30. Murine model of hypereosinophilic syndromes/chronic eosinophilic leukemia.
Yamada Y; Cancelas JA; Rothenberg ME
Int Arch Allergy Immunol; 2009; 149 Suppl 1():102-7. PubMed ID: 19494514
[TBL] [Abstract][Full Text] [Related]
31. The conformational control inhibitor of tyrosine kinases DCC-2036 is effective for imatinib-resistant cells expressing T674I FIP1L1-PDGFRα.
Shen Y; Shi X; Pan J
PLoS One; 2013; 8(8):e73059. PubMed ID: 24009732
[TBL] [Abstract][Full Text] [Related]
32. [Identification of FIP1L1-PDGFRA fusion, and expression of signal transducer and activator of transcription 5 in hypereosinophilic syndrome].
Zhang GS; Li B; Pei MF; Dai CW; Zheng WL; Shen JK
Zhonghua Yi Xue Za Zhi; 2004 Sep; 84(18):1541-4. PubMed ID: 15500716
[TBL] [Abstract][Full Text] [Related]
33. Pure red cell aplasia associated with imatinib-treated FIP1L1-PDGFRA positive chronic eosinophilic leukemia.
Tanaka H; Iwato K; Asou H; Kimura A
Intern Med; 2010; 49(12):1195-200. PubMed ID: 20558942
[TBL] [Abstract][Full Text] [Related]
34. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.
Cools J; DeAngelo DJ; Gotlib J; Stover EH; Legare RD; Cortes J; Kutok J; Clark J; Galinsky I; Griffin JD; Cross NC; Tefferi A; Malone J; Alam R; Schrier SL; Schmid J; Rose M; Vandenberghe P; Verhoef G; Boogaerts M; Wlodarska I; Kantarjian H; Marynen P; Coutre SE; Stone R; Gilliland DG
N Engl J Med; 2003 Mar; 348(13):1201-14. PubMed ID: 12660384
[TBL] [Abstract][Full Text] [Related]
35. The FIP1L1-PDGFRalpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia.
Cools J; Stover EH; Wlodarska I; Marynen P; Gilliland DG
Curr Opin Hematol; 2004 Jan; 11(1):51-7. PubMed ID: 14676627
[TBL] [Abstract][Full Text] [Related]
36. Detection of FIP1L1-PDGFRA fusion by FISH.
Ma ES; Wong KF; Wong CL; Siu LL
Br J Haematol; 2007 Aug; 138(3):279. PubMed ID: 17542982
[No Abstract] [Full Text] [Related]
37. The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib).
von Bubnoff N; Gorantla SP; Thöne S; Peschel C; Duyster J
Blood; 2006 Jun; 107(12):4970-1; author reply 4972. PubMed ID: 16754777
[No Abstract] [Full Text] [Related]
38. Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing.
Klion AD; Robyn J; Maric I; Fu W; Schmid L; Lemery S; Noel P; Law MA; Hartsell M; Talar-Williams C; Fay MP; Dunbar CE; Nutman TB
Blood; 2007 Nov; 110(10):3552-6. PubMed ID: 17709602
[TBL] [Abstract][Full Text] [Related]
39. The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia.
Cools J; Quentmeier H; Huntly BJ; Marynen P; Griffin JD; Drexler HG; Gilliland DG
Blood; 2004 Apr; 103(7):2802-5. PubMed ID: 14630792
[TBL] [Abstract][Full Text] [Related]
40. Sorafenib is effective for imatinib-resistant FIP1L1/PDGFRA T674I mutation-positive acute myeloid leukemia with eosinophilia.
Al-Riyami AZ; Hudoba M; Young S; Forrest D
Leuk Lymphoma; 2013 Aug; 54(8):1788-90. PubMed ID: 23157309
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
